The FDA approved dupilumab for eosinophilic esophagitis in 2022, and now a trial from the Consortium of Eosinophilic Gastrointestinal Disease Researchers shows the drug improves outcomes in eosinophilic gastritis, same mechanism, same immune pathway, six inches lower in the digestive tract [3]. The pattern reveals how treatment reaches rare disease patients: not through bespoke development for each condition, but through methodical testing of molecules already proven profitable in a related indication.
Dupilumab blocks interleukin-4 and interleukin-13, the cytokines that recruit eosinophils to tissue [3]. Eosinophilic diseases share this pathway regardless of whether the white blood cells infiltrate the esophagus, stomach, or duodenum. The biology suggested the drug should work in gastritis if it worked in esophagitis, but biology alone doesn't generate clinical trials, market size does. Eosinophilic esophagitis affects enough patients to justify Phase 3 development; that success funds the search for rarer cousins.
The CEGIR study recruited 74 patients with eosinophilic gastritis and qualified 41 for enrollment, a 45% attrition rate before the first dose [3]. Those 41 received dupilumab or placebo for 12 weeks [3]. The drug improved the primary outcome measure: gastric eosinophil counts dropped in treated patients compared to controls [3]. Secondary outcomes followed the same direction, histopathologic abnormalities, endoscopic findings, and transcriptomic biomarkers all showed improvement in the dupilumab arm [3].
Before researchers could test the drug, they had to define what "better" meant for a disease rare enough that consensus outcome measures didn't exist. The trial team mined data from the OMEGA study to establish endpoints [3]. You can't prove efficacy until you've agreed on what counts as improvement, and for eosinophilic gastritis that agreement had to be built from scratch using a prior observational cohort. The dupilumab trial succeeded pharmacologically, but it also succeeded epistemologically, it created the measurement framework that future trials will use.
Eosinophilic gastritis currently has no FDA-approved treatments [3]. Neither do most rare diseases, because the economics of drug development don't favor small patient populations. The dupilumab cascade, esophagitis in 2022, gastritis in this trial, and now a University of California San Francisco study extending to duodenitis, shows the logic of repurposing: prove the drug in one indication large enough to recoup development costs, then test it in progressively smaller populations where the same mechanism operates [4]. The UCSF trial will track dupilumab over 24 to 52 weeks in adolescents and adults with gastritis and duodenitis [4]. Enrollment is open [4].
The model works only when the first approval generates revenue sufficient to justify the search. Esophageal eosinophilia affects enough people to fund Phase 3 trials; gastric eosinophilia likely does not. The drug already cleared safety testing, already sits in pharmacies under the esophageal indication, already has a known dosing regimen. For the 41 patients in the CEGIR study, treatment was six inches of anatomy and one 12-week trial away from the condition dupilumab was originally approved to treat [3].
The proximity is geographic and biological, but the regulatory distance remains vast until data like these convert mechanistic plausibility into statistical proof. What began as a treatment for skin inflammation has become a probe for type 2 immunity across organ systems, each trial narrowing the gap between what the drug can do and what physicians are allowed to prescribe it for. The question now is not whether dupilumab works in eosinophilic gastrointestinal disease, but how quickly the evidence base can catch up to the biology.
